This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years. The mortality at follow-up<a href="https://solaci.org/en/2015/06/24/partner-to-5-years-tavr-is-an-effective-alternative-to-surgery-in-high-risk-patients/" title="Read more" >...</a>

This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE &gt; 18.5<a href="https://solaci.org/en/2015/06/24/uk-tavi-registry-long-term-results-of-tavi-in-the-uk/" title="Read more" >...</a>

The Cadiobrand device is implanted through a transseptal approach and makes a reduction in the mitral annulus area. The study included 24 patients with moderate mitral regurgitation (functional class III- IV) and high surgical risk. The device was successfully implanted in all cases reducing the annular size by 92 % and to the same extent<a href="https://solaci.org/en/2015/06/24/safety-and-efficacy-of-cardiobrand-device-for-percutaneous-mitral-annuloplasty/" title="Read more" >...</a>

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy of Fallot with pulmonary atresia, truncus arteriosus, transposition of great arteries with VSD, pulmonary stenosis, etc.The Melody trans catheter pulmonary valve is composed of three leaflets of bovine jugular vein mounted<a href="https://solaci.org/en/2015/06/24/melody/" title="Read more" >...</a>

Review: Two hundred twenty-four patients in a surgical plan, (coronary artery bypass grafting or valve), were randomized to cardiac surgery alone or associated with atrial ablation, (MAZE, 97% for cryoablation). The primary objective was the evaluation of sinus rhythm at 1 year by performing a Holter. The difference was 60.2% versus 35.5% in favor of<a href="https://solaci.org/en/2015/06/24/prague-12-surgical-atrial-ablation-follow-the-one-year-results/" title="Read more" >...</a>

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-clinical-events-at-3-years-follow-up-in-patients-with/" title="Read more" >...</a>

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic<a href="https://solaci.org/en/2015/06/24/partner-cohort-a-at-three-years-the-benefit-continues/" title="Read more" >...</a>

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis balloon-expandable Edwards-SAPIEN showed a mortality reduction compared with standard treatment. However, the Edwards SAPIEN device is associated with peri-procedural complications. The new generation of Edwards SAPIEN XT prosthesis incorporates significant improvements in the profile of the delivery system,<a href="https://solaci.org/en/2015/06/24/partner-2-edwards-sapien-xt-is-even-better-results-for-partner-ii-cohort-b/" title="Read more" >...</a>

Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia are unknown. We included 253 patients with severe aortic stenosis who received TAVI at 14 sites in Asia (Edwards Sapiens: 140 patients; Medtronic Core Valve: 113 patients). The success rate was<a href="https://solaci.org/en/2015/06/24/clinical-results-of-tavi-in-asia/" title="Read more" >...</a>

There is little information in the literature about the obstruction of the coronary ostia after percutaneous aortic valve implantation. 81 TAVI sites and programs and 6688 patients in total provided information on this complication. Of all, 28 patients (0.66%) developed this complication, being more frequent for balloon-expandable prosthesis and when procedures were performed &#8220;valve in<a href="https://solaci.org/en/2015/06/24/coronary-obstruction-registry-after-tavi/" title="Read more" >...</a>